"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
<p>Abstract</p> <p>Chronic obstructive pulmonary disease (COPD) represents a significant burden for healthcare systems that is expected to grow further in the future. Inhaled long-acting bronchodilators, including tiotropium, represent the cornerstone of management of COPD patients...
Main Authors: | Kostikas Konstantinos, Bouros Demosthenes |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | BMC Pulmonary Medicine |
Online Access: | http://www.biomedcentral.com/1471-2466/10/48 |
Similar Items
-
Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
by: José Alberto Neder, et al. -
Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
by: Cheng S, et al.
Published: (2017-07-01) -
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
by: Salvatore Corrao, et al.
Published: (2017-09-01) -
COPD exacerbation: Lost in translation
by: Bouros Demosthenes, et al.
Published: (2009-01-01) -
Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
by: Bishwakarma R, et al.
Published: (2017-01-01)